Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

被引:38
|
作者
Blum, K. A. [1 ]
Ruppert, A. S. [1 ]
Woyach, J. A. [1 ]
Jones, J. A. [1 ]
Andritsos, L. [1 ]
Flynn, J. M. [1 ]
Rovin, B. [2 ]
Villalona-Calero, M. [3 ]
Ji, J. [4 ]
Phelps, M. [4 ]
Johnson, A. J. [1 ]
Grever, M. R. [1 ]
Byrd, J. C. [1 ,4 ]
机构
[1] Ohio State Univ, Div Hematol, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Div Nephrol, Dept Internal Med, Columbus, OH 43210 USA
[3] Arthur G James Comprehens Canc Ctr, Div Med Oncol, Dept Internal Med, Columbus, OH USA
[4] Ohio State Univ, Div Med Chem & Pharmacol, Coll Pharm, Columbus, OH 43210 USA
关键词
chronic lymphocytic leukemia; flavopiridol; tumor lysis syndrome; CONTINUOUS-INFUSION; FLUDARABINE; THERAPY; CYCLOPHOSPHAMIDE; GUIDELINES; MANAGEMENT; CONSENSUS; SCHEDULE; CANCER; CELLS;
D O I
10.1038/leu.2011.109
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In univariable analysis, female gender, greater number of prior therapies, Rai stages III-IV, adenopathy >= 10 cm, splenomegaly, del(11q), decreased albumin and increased absolute lymphocyte count, white blood cell count (WBC), beta 2-microglobulin, and lactate dehydrogenase were associated (P<0.05) with TLS. In multivariable analysis, female gender, adenopathy >= 10 cm, elevated WBC, increased beta 2-microglobulin, and decreased albumin were associated with TLS (P<0.05). With respect to patient outcomes, 49 and 44% of patients with and without TLS, respectively, responded to flavopiridol (P=0.71). In a multivariable analysis, controlling for number of prior therapies, cytogenetics, Rai stage, age and gender, progression-free survival (PFS) was inferior in patients with TLS (P=0.01). Female patients and patients with elevated b2-microglobulin, increased WBC, adenopathy >= 10cm and decreased albumin were at highest risk and should be monitored for TLS with flavopiridol. TLS does not appear to be predictive of response or improved PFS in patients receiving flavopiridol. Leukemia (2011) 25, 1444-1451; doi: 10.1038/leu.2011.109; published online 24 May 2011
引用
收藏
页码:1444 / 1451
页数:8
相关论文
共 50 条
  • [41] The cyclin-dependent kinase inhibitor flavopiridol inhibits glycogen phosphorylase and affects glucose metabolism.
    Kaiser, AU
    Nishi, K
    Walsh, DA
    Gorin, FA
    Bradbury, EM
    Schnier, JB
    CLINICAL CANCER RESEARCH, 1999, 5 : 3754S - 3754S
  • [42] PHASE I STUDY OF THE CYCLIN-DEPENDENT KINASE (CDK) INHIBITOR DINACICLIB (SCH 727965) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Jones, J.
    Flynn, J.
    Andritsos, L.
    Johnson, A.
    Blum, K.
    Wiley, E.
    Small, K.
    Grever, M.
    Graef, T.
    Bannerji, R.
    Byrd, J.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [43] Spontaneous tumor lysis syndrome in a patient of chronic lymphocytic leukemia
    Gogia, Ajay
    Raina, Vinod
    Iqbal, Nida
    Murugan, Vijaya
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2014, 35 (01) : 120 - 120
  • [44] Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells
    Motwani, M
    Li, XK
    Schwartz, GK
    CLINICAL CANCER RESEARCH, 2000, 6 (03) : 924 - 932
  • [45] Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia
    Tsirigotis, P
    Pappa, V
    Labropoulos, S
    Papageorgiou, S
    Kontsioti, F
    Dervenoulas, J
    Papageorgiou, E
    Panani, A
    Mantzios, G
    Economopoulos, T
    Raptis, S
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (03) : 230 - 236
  • [46] Contribution of Cyclin-dependent Kinase Inhibitor 1B Genotypes to Childhood Leukemia Risk
    Pei, Jen-Sheng
    Chang, Wen-Shin
    Hsu, Pei-Chen
    Chen, Chao-Chun
    Yang, Ya-Chen
    Hsu, Shih-Wei
    Hsu, Yuan-Nian
    Wang, Yun-Chi
    Wang, Chung-Hsing
    Tsai, Chia-Wen
    Bau, Da-Tian
    IN VIVO, 2022, 36 (04): : 1637 - 1642
  • [47] Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol
    Nelson, PJ
    D'Agati, VD
    Gries, JM
    Suarez, JR
    Gelman, IH
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) : 921 - 929
  • [48] Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients
    Chim, C. S.
    Fung, T. K.
    Wong, K. F.
    Lau, J. S.
    Law, M.
    Liang, R.
    JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (09) : 921 - 926
  • [49] The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
    Konig, A
    Schwartz, GK
    Mohammad, RM
    AlKatib, A
    Gabrilove, JL
    BLOOD, 1997, 90 (11) : 4307 - 4312
  • [50] Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model
    Saisomboon, Saowaluk
    Kariya, Ryusho
    Vaeteewoottacharn, Kulthida
    Wongkham, Sopit
    Sawanyawisuth, Kanlayanee
    Okada, Seiji
    HELIYON, 2019, 5 (05)